Analysis of the intestinal microbiota in COVID-19 patients and its correlation with the inflammatory factor IL-18Original paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined how the gut microbiota changes in COVID-19 and whether those changes relate to the intestinal inflammatory cytokine IL-18. SARS-CoV-2 mainly infects the lung but may also infect the intestine. Researchers compared gut bacteria in COVID-19 patients against healthy controls and seasonal flu patients. They also measured IL-18 in fecal samples and compared levels by whether stool tested positive for SARS-CoV-2 RNA.
Who was studied?
The subjects were COVID-19 patients, compared against two reference groups: healthy controls and seasonal influenza patients. This was a human clinical study analyzing fecal samples. The comparison groups let the team distinguish COVID-19 specific changes from general respiratory infection. Fecal specimens were used both for microbiota profiling and for measuring the inflammatory cytokine IL-18.
What were the most important findings?
Compared with healthy controls and seasonal flu patients, COVID-19 patients had significantly reduced gut microbial diversity, with increased opportunistic pathogens. This points to gut dysbiosis in COVID-19. Fecal IL-18 levels were higher in COVID-19 patients than in either healthy controls or flu patients. IL-18 was even higher in fecal supernatants from patients whose stool tested positive for SARS-CoV-2 RNA than in those that tested negative, linking intestinal viral presence to inflammation.
What are the greatest implications of this study?
The findings suggest gut microbiota shifts in COVID-19 may contribute to intestinal production of inflammatory cytokines like IL-18. That inflammation could potentially feed into a wider cytokine storm. The associations are correlational and do not establish that dysbiosis causes severe disease. Still, the results support monitoring the gut in COVID-19 and studying whether microbiota or IL-18 could serve as markers of intestinal involvement.